The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Rima Kulkarni, Rebecca Hluhanich, Damian M McColl, Michael D Miller, Kirsten L White
Index: Antimicrob. Agents Chemother. 58(10) , 6145-50, (2014)
Full Text: HTML
Abstract
Highly active antiretroviral therapy (HAART) involves combination treatment with three or more antiretroviral agents. The antiviral effects of combinations of emtricitabine (FTC) plus tenofovir (TFV) plus antiretroviral agents of all the major drug classes were investigated. Combinations of FTC and TFV with a nonnucleoside reverse transcriptase inhibitor (NNRTI) (efavirenz or rilpivirine) or with a protease inhibitor (PI) (atazanavir, lopinavir, or darunavir) showed additive to synergistic anti-HIV-1 activity. FTC-TFV with an HIV-1 integrase strand transfer inhibitor (INSTI) (elvitegravir or raltegravir) showed the strongest synergy. Anti-HIV-1 synergy suggests enhancement of individual anti-HIV-1 activities within cells that may contribute to potent treatment efficacy and open new areas of research into interactions between reverse transcriptase (RT) and integrase inhibitors. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Related Compounds
Related Articles:
2015-11-01
[Dis. Model Mech. 8 , 1441-55, (2015)]
2014-10-01
[Food Chem. Toxicol. 72 , 13-9, (2014)]
2014-06-01
[Food Chem. Toxicol. 68 , 117-27, (2014)]
2015-01-01
[Drug Metab. Dispos. 43(1) , 147-53, (2014)]
2014-09-01
[Antimicrob. Agents Chemother. 58(9) , 5036-46, (2014)]